Characteristic, n (%) | pCR | non-pCR | P | ||
---|---|---|---|---|---|
pT0N0 | pT0N1-3 | pT1-4N0 | pT1-4N1-3 | ||
n=25 | n=10 | n=40 | n=40 | ||
Median age (range) | 63 (44–77) | 65 (53–75) | 66 (43–74) | 63 (41–75) | 0.2402 |
Gender | 0.7178 | ||||
Female | 5 (20.0) | 1 (10.0) | 8 (20.0) | 5 (12.5) | |
Male | 20 (80.0) | 9 (90.0) | 32 (80.0) | 35 (87.5) | |
Tumor location | 0.8228 | ||||
Upper | 5 (20.0) | 2 (20.0) | 8 (20.0) | 9 (22.5) | |
Middle | 9 (36.0) | 4 (40.0) | 18 (45.0) | 21 (52.5) | |
Lower | 11 (44.0) | 4 (40.0) | 14 (35.0) | 10 (25.0) | |
Tumor differentiation | 0.5425 | ||||
Not poorly | 20 (80.0) | 8 (80.0) | 36 (90.0) | 36 (90.0) | |
Poorly | 5 (20.0) | 2 (20.0) | 4 (10.0) | 4 (10.0) | |
Depth of invasion (cT) | 0.0567 | ||||
T1-2 | 5 (20.0) | 3 (30.0) | 2 (5.0) | 3 (7.5) | |
T3-4 | 20 (80.0) | 7 (70.0) | 38 (95.0) | 37 (92.5) | |
Lymph node metastasis (cN) | 0.5858 | ||||
N1 | 18 (72.0) | 8 (80.0) | 26 (65.0) | 24 (60.0) | |
N2-3 | 7 (28.0) | 2 (20.0) | 14 (35.0) | 16 (40.0) | |
Distant metastasis (cM) | 0.2138 | ||||
M0 | 19 (76.0) | 10 (100) | 36 (90.0) | 35 (87.5) | |
M1 (lymph node) | 6 (24.0) | 0 (0) | 4 (10.0) | 5 (12.5) | |
Clinical stage(cStage) | 0.1051 | ||||
I | 1 (4.0) | 1 (10.0) | 2 (5.0) | 0 (0) | |
II | 3 (12.0) | 2 (20.0) | 0 (0) | 3 (7.5) | |
III | 14 (56.0) | 6 (60.0) | 34 (85.0) | 31 (77.5) | |
IVA | 1 (4.0) | 1 (10.0) | 0 (0) | 1 (2.5) | |
IVB | 6 (24.0) | 0 (0) | 4 (10.0) | 5 (12.5) | |
Recurrence | 0.0456a | ||||
Presence | 5 (20.0) | 4 (40.0) | 15 (37.5) | 22 (55.0) | |
Absence | 20 (80.0) | 6 (60.0) | 25 (62.5) | 18 (45.0) | |
Prognosis | 0.3115 | ||||
Alive | 22 (88.0) | 6 (60.0) | 27 (67.5) | 24 (60.0) | |
Dead with ESCC | 2 (8.0) | 3 (30.0) | 10 (25.0) | 14 (35.0) | |
Dead with other diseases | 1 (4.0) | 1 (10.0) | 3 (7.5) | 2 (5.0) |